Delhi’s Pharma University nears landmark; Makes breakthrough Ayurvedic treatment for Covid-19

By: |
July 28, 2021 12:38 PM

According to DPSRU Vice-Chancellor Prof Ramesh K. Goyal, Coroquil-Zn is the first formulation that modulates the SARS-Cov-2 virus’ ACE-2 levels and/or receptors, enabling it to prevent and treat Covid-19 symptoms and prevent post-Covid complications.

Ayurveda treatmentThe Phase III trials studied the response of the formulation in 120 patients in the 23-75 age group, who displayed significant viral load reduction.

The Delhi Pharmaceutical Sciences and Research University (DPSRU) is on the cusp of a breakthrough Ayurvedic treatment for Covid-19.

The university has completed Phase III clinical trials of Coroquil-Zn, developed in collaboration with Remedium Therapeutics, in Covid-19 patients with mild and moderate symptoms at a hospital in Bengaluru. It is now awaiting the final nod from the Union Ministry of AYUSH to market the product. The novel repurposed Ayurveda ingredients of edible plants were identified by Prof C.R. Babu, head of the Centre for Environmental Management of Degraded Ecosystem at Delhi University, with Zinc oxide.

The Phase III trials studied the response of the formulation in 120 patients in the 23-75 age group, who displayed significant viral load reduction. According to the study, 48%, 94.8%, and 100% of the patients returned negative RT-PCR reports on the fifth, seventh, and 14th day of treatment, respectively. The patients also recovered their taste and smell within eight days and were discharged from hospital sooner than patients undergoing standard care.

According to DPSRU Vice-Chancellor Prof Ramesh K. Goyal, Coroquil-Zn is the first formulation that modulates the SARS-Cov-2 virus’ ACE-2 levels and/or receptors, enabling it to prevent and treat Covid-19 symptoms and prevent post-Covid complications.

“I’m surprised that ACE-2, a key target for the virus, treatments for Covid-19 haven’t been considered for the development of effective therapeutics,” Prof Goyal said. Coroquil-Zn has a twofold effect on ACE-2 — it reduces the virus’ entry and replication and also modulates the Renin Angiotensin system, responsible for immune disturbances that can lead to heart, respiratory, neurological, and other complications.

Cell-based studies conducted at the University of Missouri found that Coroquil-Zn reduced the viral load by reducing the ACE-2 receptors’ functions. The varsity is now conducting in vivo studies in animals to establish its post-Covid effects in brain, lungs, and other organs.

Prof Goyal, who was speaking during an interaction to celebrate the centenary of the discovery of Insulin, said the drug is likely to be effective in tackling even the highly contagious Delta variant of the coronavirus. He added that drug can also be used as a dietary supplement. “I’m thankful to Delhi Lieutenant Governor (and DPSRU Chancellor) Anil Baijal for encouraging us to work towards this treatment,” he said. It was Baijal who pointed the varsity team to the Aravalli Biodiversity Park, where they identified and collected the plant used in the formulation.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19 vaccination drive: Two-thirds of adult population vaccinated with first dose
2Novavax, SII apply to WHO for emergency use listing of COVID vaccine
3Not many places left for COVID-19 virus to evade immunity: UK vaccine creator